Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:962 |
Name | neurofibroma |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer nervous system cancer peripheral nervous system neoplasm peripheral nerve sheath neoplasm neurofibroma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02096471 | Phase II | PD-0325901 | MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 | Completed | USA | 0 |
NCT02839720 | Phase II | Selumetinib | Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma | Completed | USA | 0 |
NCT03259633 | Expanded access | Selumetinib | An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1 | Approved for marketing | USA | 0 |
NCT04283669 | Phase II | Crizotinib | Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas (NF110) | Active, not recruiting | USA | 0 |
NCT04374305 | Phase II | Brigatinib | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) (INTUITT-NF2) | Recruiting | USA | 0 |
NCT04750928 | Phase Ib/II | Abemaciclib | Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas | Recruiting | USA | 0 |
NCT05253131 | Phase Ib/II | AZD5153 + Durvalumab + Selumetinib AZD5153 + Selumetinib | Trial of Selumetinib and AZD5153 With Durvalumab for Sarcomas | Not yet recruiting | USA | 0 |